Drug intelligence / Profile preview

4HF-01

Development stage: Preclinical
Lead developer: 4HF Biotec
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

4HF-01 is an experimental small molecule drug conjugate (SMDC) being developed by 4HF Biotec for the treatment of prostate cancer. The drug is currently in the discovery phase, specifically undergoing in silico and medicinal chemistry optimization. 4HF Biotec utilizes an AI-driven platform to identify novel cancer targets and design SMDCs that aim to deliver cytotoxic payloads specifically to tumor cells, thereby increasing efficacy and reducing off-target toxicity. As of the current pipeline status, the specific molecular target for 4HF-01 has not been publicly disclosed.

Beyond the preview

Go deeper on 4HF-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4HF-01.

Explore the full profile